AscellaHealth: Providing a Rare and Special Perspective

Cell and gene therapies (CGTs) and other rare disease specialty therapies hold immense potential for treating patients with debilitating conditions. However, there are many barriers to access these novel therapies including the exorbitant costs associated with these treatments which pose a significant challenge for patients and stakeholders, such as employers, government-funded healthcare programs, commercial payers, and healthcare providers. To overcome this issue, stakeholders can embrace innovative solutions as well as value-based pricing, outcome based agreements, risk-sharing models, and innovative reimbursement strategies.

To read more, click here.

To view the article in the Healthcare Outlook e-zine, click here.